Taiwan CNS Drug Companies and Pipelines
As of October 23, 2026, this table includes neurological and pain drug or cell-therapy programs at 7 Taiwan companies, including preclinical programs and completed or terminated trials. [1] [2] [3] [4] [5] [6] [7] [8]
Selected indications include acute and chronic stroke, Alzheimer disease, schizophrenia and postsurgical pain; the selected TLC590 trial is Phase 3 and active, not recruiting, while the selected SyneuRx NaBen trial is terminated. [1] [2] [3] [4] [5] [6] [7] [8]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| Lumosa Therapeutics Company source | 6535 | LT3001 with endovascular thrombectomy (LT3001-203) | Acute ischemic stroke undergoing endovascular thrombectomy | Phase 2; ACTIVE_NOT_RECRUITING (NCT05198323) | 2026-08-31 Stage source ACTIVE_NOT_RECRUITING | — |
| Foresee Pharmaceuticals Company source | 6576 | FP-018 (cariprazine long-acting injection) | Schizophrenia and bipolar disorder | Preclinical; classified as preclinical-stage on the current company R&D page | 2026-10-23 Stage source preclinical-stage | — |
| Excelsior Biopharma Company source | 6496 | EX039 (EX-039) Product source | Mild Alzheimer disease; add-on to acetylcholinesterase inhibitors | Phase 2; RECRUITING (NCT05413655) | 2025-02-26 Stage source RECRUITING | — |
| Taiwan Liposome Company (delisted in 2021) Company source | 4152 | TLC590 (long-acting local ropivacaine injection) Product source | Postsurgical pain following bunionectomy | Phase 3; ACTIVE_NOT_RECRUITING (NCT07222748) | 2026-07-02 Stage source ACTIVE_NOT_RECRUITING | — |
| Gwo Xi Stem Cell Applied Technology Company source | 6704 | GXNPC1 (autologous adipose-derived stem cells) Product source | Chronic stroke | Phase 2 COMPLETED (NCT04088149); Phase 3 trial authorized in August 2026 | 2024-09-19 Stage source COMPLETED | — |
| SyneuRx International (Taiwan) Company source | 6575 (former emerging-stock ticker; terminated 2023) | NaBen (sodium benzoate; SNR-04) | Add-on treatment for schizophrenia in adults | Phase 2b/3; TERMINATED due to commercial strategy (NCT02261519) | 2024-05-24 Stage source TERMINATED | — |
| Ever Supreme Bio Technology Company source | 6712 | UMSC01 (allogeneic umbilical cord mesenchymal stem cells) | Acute ischemic stroke | Phase 1; COMPLETED (NCT04434768) | 2026-09-23 Stage source COMPLETED | — |
Scope and public-document limits
This is a verified selection rather than an industry census or a list of active trials. Pain programs may act locally in the periphery. Registry statuses retain each study update date; trial authorization, completion and product approval are distinct.